Revealing the mechanism for covalent inhibition of glycoside hydrolases by carbasugars at an atomic level by Ren, Weiwu et al.
ARTICLE
Revealing the mechanism for covalent inhibition
of glycoside hydrolases by carbasugars
at an atomic level
Weiwu Ren 1, Robert Pengelly2, Marco Farren-Dai1, Saeideh Shamsi Kazem Abadi3, Verena Oehler2,
Oluwafemi Akintola1, Jason Draper1, Michael Meanwell1, Saswati Chakladar1, Katarzyna Świderek 4,
Vicent Moliner 4, Robert Britton1, Tracey M. Gloster 2 & Andrew J. Bennet 1
Mechanism-based glycoside hydrolase inhibitors are carbohydrate analogs that mimic the
natural substrate’s structure. Their covalent bond formation with the glycoside hydrolase
makes these compounds excellent tools for chemical biology and potential drug candidates.
Here we report the synthesis of cyclohexene-based α-galactopyranoside mimics and the
kinetic and structural characterization of their inhibitory activity toward an α-galactosidase
from Thermotoga maritima (TmGalA). By solving the structures of several enzyme-bound
species during mechanism-based covalent inhibition of TmGalA, we show that the Michaelis
complexes for intact inhibitor and product have half-chair (2H3) conformations for the
cyclohexene fragment, while the covalently linked intermediate adopts a ﬂattened half-chair
(2H3) conformation. Hybrid QM/MM calculations conﬁrm the structural and electronic
properties of the enzyme-bound species and provide insight into key interactions in the
enzyme-active site. These insights should stimulate the design of mechanism-based glyco-
side hydrolase inhibitors with tailored chemical properties.
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Of the three main biological polymeric building blocks,carbohydrates are the most structurally diverse. UnlikeDNA and proteins, their sequence is not templated and
instead relies on the activity and speciﬁcity of enzyme-catalyzed
processes that use carbohydrates and their derivatives as sub-
strates1. For example, glycoside hydrolases (GHs)2 are ubiquitous
in nature and catalyze the removal of carbohydrates from a range
of biomolecules. Thus GHs are not only critical for digesting
carbohydrates and degrading plant biomass but are also key
players in pathogen infection, antibacterial defense, and many
other essential cellular processes3. As a result, natural product
inhibitors of GHs, including castanospermine4, mannostatin A5,
nojirimycin6, and acarbose7, are often pursued as therapeutics
(Fig. 1a). For example, starting with the natural product Neu2e-
n5Ac8 medicinal chemical approaches gave rise to the inﬂuenza
therapeutic oseltamivir (Fig. 1b)9.
Of note, many GH inhibitors incorporate a basic nitrogen
atom6 that mimics the nascent charge of pyranosylium ion-like
transition states10 (Fig. 2a). Structural elements that mimic
enzyme-bound substrates11 and preclude a ground state chair
conformation include sp2-hybridized ring atoms12, ﬁve-
membered rings5, or bicyclic scaffolds4,13 and are also common
features in GH inhibitors. Considering that GHs exhibit high
catalytic proﬁciencies (~1017 M–1)14,15, deciphering structures
along the reaction pathway can lead to improved understanding
of their catalytic mechanism and profoundly affect inhibitor
design16. Of the GH mechanisms that catalyze glycosidic bond
hydrolysis, most that occur with retention of stereochemistry rely
on two active site aspartic acid (Asp) and/or glutamic acid (Glu)
residues (Fig. 2a)1,10,17,18. These enzymes employ sequential SN2-
like reactions, each involving an inversion of conﬁguration, where
the ﬁrst generates a covalent glycosyl-enzyme intermediate and
the second one hydrolyzes the intermediate1,10,19–21. Previously,
we exploited the ability of GHs to stabilize anomeric positive
charge development during glycosylation and deglycosylation in
the design of cyclohexene22 (e.g., 1) and cyclopropylmethyl22–24
mechanism-based covalent GH inhibitors. The cyclohexene
inhibitors likely undergo a pseudo-glucosylation reaction as
shown for 1 (Fig. 2b)22. Recently, Danby and Withers reported
that the related cyclohexene carbaglucose analog 2 was a substrate
for several β-glucosidases (Fig. 2c)25. Here we present the
synthesis of three cyclohexene-based mimics of galactose
including a 2-deoxy-2-ﬂuorogalactose analog and the kinetic
characterization of their reactions with an α-galactosidase from
Thermotoga maritima (TmGalA). The GH inhibitory activity of
these compounds is compared with that of a 2-deoxy-2-
ﬂuoroglycoside and a cyclophellitol analog, both established
inactivators26,27. We also present the structural characterization
of our carbasugars with TmGalA in the form of Michaelis com-
plexes for the inhibitor (with an active site mutant), the reaction
products, and most critically, the covalent adduct formed during
the turnover of our cyclohexene mimic of 2-deoxy-2-
ﬂuorogalactose. Using a combination of quantum mechanics/
molecular mechanics (QM/MM) methods, we also provide sup-
port for the X-ray structural results by localizing and character-
izing the relevant enzyme-bound states.
Results
Synthesis of cyclohexene galactose analogs. Previously, we have
reported that the cyclohexene carbasugar 1 is a covalent inhibitor
of yeast α-glucosidase (GH13 family)22 and that the reaction takes
place through a covalent enzyme-bound intermediate, which
undergoes slow hydrolysis to regenerate active enzyme. That is,
covalent inhibitors result in reversible loss of enzyme activity, a
process that is irreversible with covalent inactivators. As a result,
we hypothesized that a galacto-conﬁgured analog would cova-
lently label a GH36 α-galactosidase, a member of GH clan-D, that
has as its main structural element a (β/α)8 fold, which is the same
protein fold as found for family GH13. Notably, these two GH
families bind bicyclo[4.1.0]heptyl amines (with the appropriate
stereochemistry) tightly13,28. Initially, we used a tetra-O-benzyl-
cyclohexenol24 that was arylated via an SNAr reaction after
debenzylation with BCl3 in CH2Cl2 to give covalent inhibitor 3a.
Unfortunately, after performing a variety of crystal soaking
experiments with inhibitor 3a, only structures of the Michaelis
complex (with an active site mutant) and product complex were
obtained and no covalent adduct was observed (vide infra). In an
effort to characterize structurally the covalent intermediate, we
elected to (i) enhance the leaving group ability of the pseudo-
aglycone and (ii) structurally modify the substituents on the
cyclohexene ring in an effort to increase the lifetime of the
covalent intermediate. Thus we targeted the galacto conﬁgured
2,4-dinitrophenyl ether 3b and the corresponding 2-ﬂuoro analog
4, with the expectation that covalent intermediates would form
faster and that the 2-ﬂuoro group in 4 would decrease the rate of
hydrolysis of the covalent intermediate29,30.
Synthesis of the 2-hydroxycarbasugar 3b started with 2-deoxy-
L-ribose-derived aldehyde 9, which was subjected to a proline-
catalyzed α-chlorination-aldol reaction (Fig. 3)31,32 that effects a
dynamic kinetic resolution involving the racemization of
chloroaldehydes 10 and 11 and delivered the anti-aldol-syn-
chlorohydrin 13 in good yield and excellent diastereoselectivity
(dr > 20:1)31. With chlorohydrin 13 in hand, several oleﬁnation
methods were examined and we found that a Julia–Kocienski
reaction31 using the lithium anion derived from methylsulfonyl
phenyltetrazole delivered the diene 14 without requiring protec-
tion of the secondary alcohol function. Unfortunately, attempts to
effect a ring closing metathesis (RCM)33–35 on this material using
various catalysts returned only starting material. Also, removal of
the TIPS protecting group (TBAF) followed by treatment with
Grubbs’ ﬁrst33 or second-generation34 catalyst resulted primarily
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in isomerization to the ethyl ketone 1736,37. In an effort to
circumvent these problems and facilitate the desired RCM
reaction, we converted chlorohydrin 14 into the corresponding
syn-epoxide by treatment with CsOH in hot EtOH-H2O. While
the TIPS-protected epoxyalcohol was not a productive substrate
for a RCM, following the removal of the silyl protecting group the
corresponding alcohol 15 was readily transformed into cyclohex-
ene 16 using either Stewart–Grubbs'35 or Grubbs’ second-
generation catalyst34. From here, conversion into the protected
carbasugar simply involved reaction of the epoxy alcohol 16 with
CO2 and CsCO3 in warm dimethylformamide (DMF), which
afforded the carbonate 18 in excellent yield. Finally, removal of
the carbonate and reaction of the resulting triol with 2,4-
dinitroﬂuorobenzene23 afforded a mixture of arylated carbasugars
from which the targeted dinitrophenyl adduct 3b could be
isolated by preparative thin-layer chromatography (Supplemen-
tary Methods and Supplementary Figs. 8–21).
The corresponding 2-ﬂuorocarbasugar 4 was accessed follow-
ing a similar route to that described above (Fig. 4). However, we
modiﬁed our previously reported α-chlorination aldol reaction by
ﬁrst effecting a proline-catalyzed α-ﬂuorination32,38–40 of alde-
hyde 9 using Selectﬂuor in DMF followed directly by reaction of
the resulting unstable α-ﬂuoroaldehyde (not shown) with
dioxanone 12 in CH2Cl2. This subsequent proline-catalyzed aldol
reaction proceeded smoothly to afford ﬂuorohydrin 19 as a single
diastereomer.
To mitigate degradation of the unstable aldol adduct 19, the
crude reaction product was subjected directly to the optimized
Julia–Kocienski oleﬁnation conditions41, which afforded the
diene 20 as a stable and isolable intermediate. From here,
acetylation of the free alcohol provided diene 21, which following
removal of the TIPS protecting group, underwent RCM using
Grubbs’ second-generation catalyst34 to afford protected 2-
ﬂuorocarbasugar 22 in excellent overall yield. Finally, arylation
of the free alcohol function and global deprotection provided the
target 2-ﬂuorocarbasugar 4 in good yield (Supplementary
Methods and Supplementary Figs. 22–29).
Evaluation of GH36 α-galactosidase covalent inhibitors. With
the target molecules in hand, we ﬁrst assayed the GH36 family α-
galactosidase from T. maritima (TmGalA) with activated carba-
sugar analog 3b, which was turned over within 10 min and is
therefore considered a poor substrate for TmGalA (Table 1,
Supplementary Fig. 1). Of note, we observed (using 1H nuclear
magnetic resonance spectroscopy in D2O) that compound 3b
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undergoes an intramolecular rearrangement to give the isomer in
which the aryloxy group is attached to C-2 (i.e., 23, Supple-
mentary Fig. 2) with a ﬁnal equilibrium position (in D2O) is ~2:1
in favor of 3b (Supplementary Figs.30 and 31). As a result, our
measured kinetic parameters kcat and kcat/Km for the hydrolysis of
3b by TmGalA (Table 1) are lower limits if, as expected, the
enzyme does not bind the C2 aryloxy isomer.
Next we measured the kinetic parameters for turnover of 4 by
TmGalA (Table 1: Supplementary Fig. 3a shows a standard
Michaelis–Menten plot for this hydrolysis reaction) and found
that the apparent binding constant (Km) is in the low μM range.
This result suggests that pseudo-deglycosylation of 4 is rate-
limiting25 and that the replacement of the 2-hydroxyl group with
a ﬂuorine results in accumulation of the covalent intermediate.
Consequently, we undertook a sequential mixing stopped-ﬂow
experiment to measure the rate constants for the pseudo-
glycosylation reaction42. Plots of remaining α-galactosidase
activity against incubation time for four concentrations of 4 are
shown in Supplementary Fig. 4. It is clear from these stopped-
ﬂow data of rate constant versus inhibitor concentration
(Supplementary Fig. 3b) that we can only calculate the second-
order rate constant kinact/Ki from these covalent labeling
experiments. We next compared our covalent inhibitor with the
corresponding α-galacto analogs from two well-characterized
classes of GH inactivators. Speciﬁcally, we synthesized both 2,4-
dinitrophenyl 2-deoxy-2-ﬂuoro-α-D-galactopyranoside 7 and the
cyclophellitol analog 8 following literature procedures43,44 with
minor modiﬁcations (Supplementary Methods and Supplemen-
tary Figs. 32 and 33). Of note, we observed no time-dependent
decrease in TmGalA activity in the presence of 7; rather we
determined that it is a poor substrate for GH36 α-galactosidase
(Table 1, Supplementary Fig. 5). As reported for the human
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Table 1 Kinetic parameters for the TmGalA-catalyzed reactions with 3b and 4
Hydrolysis substrates kcat (s–1) kcat/Km (M–1 s–1) Km (μM)
3b (3.78 ± 0.06) × 10–2 a (2.25 ± 0.19) × 104 1.68 ± 0.14
4 (2.29 ± 0.11) × 10–4 b 56 ± 13 4.1 ± 0.9
7 3.04 ± 0.32 1200 ± 160 253 ± 8
4-NPGc (D387A) (3.60 ± 0.03) × 10–2 196 ± 6 184 ± 7
Inhibitor/inactivator kinact (s–1) kinact/Ki (M–1 s–1) Ki (μM)
4 id 143 ± 5 id
8 (1.38 ± 0.05) × 10–4 0.86 ± 0.10 161 ± 18
Conditions for all experiments were T= 37 °C in 50mM HEPES buffer, pH 7.4, quoted errors (±) are the standard errors for the ﬁts of kinetic data to either the Michaelis-Menten equation (all values
except for inactivation by 4) or a linear equation
id; indeterminable
akcat= (9.7 ± 2.3) × 10–2 s–1 corrected value based on the inactivation data for 4, which does not assume 100% activity
bkcat= (5.9 ± 1.3) × 10–4 s–1 calculated from the inactivation data for 4
c4-NPG= 4-nitrophenyl α-d-galactopyranoside; values for wild-type TmGalA-catalyzed hydrolysis of 4-NPG are: kcat= 33 s–1, and kcat/Km= 6.2 × 105M–1 s–1 (ref.45)
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GH27 enzyme44, cyclophellitol analog 8 forms the covalent
intermediate with GH36 α-galactosidase in a time-dependent
manner that is characterized by a second-order rate constant that
is about 23,000-fold lower than that for 3b (Table 1, Supplemen-
tary Figs. 6 and 7).
Structural insights into carbasugar inhibition of TmGalA.
With the aim of delineating the conformational itinerary for
intermediates along the reaction path, we undertook structural
studies to observe enzyme-bound species during the covalent
inhibition of TmGalA by carbasugar 3a. In order to obtain a
complex with intact 3a, we employed a D387A mutant of
TmGalA in which the acid/base aspartic acid is mutated to ala-
nine; this mutant displays an approximate 3100-fold reduction in
its second-order rate constant (kcat/Km) relative to wild-type45 for
the hydrolysis of 4-nitrophenyl α-D-galactopyranoside (Table 1).
Crystals of TmGalA D387A that were soaked with 3a for 2 h
diffracted to 2.20 Å resolution and the structure was solved using
molecular replacement with apo TmGalA (PDB 5M0X) as the
search model. We note that the active site contains electron
density consistent with a Michaelis complex of an intact molecule
of 3a bound (Fig. 5a). The carbasugar moiety displays a 2H3 half
chair conformation with key interactions between the C6-OH
with Asp221; the C4-OH with Trp257, Asp220, and Lys325; and
the C3-OH with Lys325, Arg383, and Tyr191. The C2-OH and
the 3,5-diﬂuorophenyl leaving group of 3a form no interactions
with TmGalA, and 3a itself has no interactions with bound water
molecules.
To obtain structural information regarding the enzyme-bound
species, 3a was also soaked with wild-type TmGalA crystals.
Following an overnight soak with 3a, the structure solved using
data to 1.22 Å resolution revealed electron density consistent with
the hydrolyzed form 5 in the active site of TmGalA (Fig. 5b). The
interactions in the active site were essentially the same as for 3a
(Fig. 5c), except for the addition of hydrogen bonds between the
C2-OH with Arg383 and Asp387, and C1-OH with Asp387 and a
water molecule. Thus, within the overnight timeframe 3a had
been hydrolyzed with retention of stereochemistry at the pseudo-
anomeric center, yielding a Michaelis complex of the reaction
product. In an effort to observe the covalent intermediate derived
from 3a, crystals were soaked for various time periods (from 5 s
to 8 h) with 3a but did not yield any additional information. We
therefore turned our attention to obtaining structural insights of
TmGalA with 4, for which the covalent intermediate has a longer
half-life (vide infra). Co-crystallization of the D387A mutant with
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4 produced crystals that diffracted to 1.72 Å resolution. The active
site contained electron density consistent with an intact molecule
of 4 bound (Fig. 6a), which again displayed a 2H3 half chair
conformation, and identical interactions to those described for
the complex with 3a.
To obtain structural information on the interactions made
between 4 and wild-type TmGalA, crystals were grown and then
soaked with the inhibitor for various periods of time. Following a
1 h soak with 4, the structure, solved using data to 1.42 Å
resolution, revealed electron density in the active site of TmGalA
consistent with the hydrolyzed carbasugar 6 (Fig. 6b) and active
site interactions that were identical to those described above for
the complex with 5. Thus, within this timeframe 4 had been
hydrolyzed with retention of stereochemistry. However, crystals
that were soaked for a much shorter period of time (~2 min) with
4 led to a structure, solved using data to 1.77 Å resolution, where
the electron density showed the covalent adduct of the carbasugar
with the nucleophile Asp327 of TmGalA (Fig. 6c). Of note, in
these three structures (Fig. 6) there are no direct interactions
between the ligand and any water molecule.
Structural insights from QM/MM simulations. Structures of the
key stable states in the catalytic cycle for covalent inhibition of
TmGalA by carbasugar 4 and the subsequent hydrolysis step were
localized and optimized by means of hybrid QM/MM calculations
(see Methods section). Snapshots of the active site corresponding
to the Michaelis complex E:I, covalent intermediate E-I, and the
Michaelis product complex E:P, obtained at density functional
theory (DFT)/MM level are shown in Fig. 7. Following optimi-
zation of the enzyme-bound species on the reaction pathway, the
conformations of the six-membered ring were classiﬁed using the
Cremer–Pople ring puckering coordinates46 and the corre-
sponding angles used in Hill and Reilly method47 (Supplementary
Fig. 36 and Supplementary Table 4).
Discussion
The minimal kinetic scheme for covalent inhibition of a GH by
carbasugars is shown in Fig. 8. That is, the covalent labeling of
TmGalA by 4 involves rapid formation of the covalent inter-
mediate (k3), from the ﬁrst-formed Michaelis complex (E:I), that
is slowly hydrolyzed (k5) to regenerate active enzyme (Fig. 8a).
The appropriate equations for the full catalytic cycle involving
enzyme-catalyzed turnover of 4 are given in Fig. 8b. Moreover,
when the glycosylated intermediate accumulates (k3 » k5) the
kinetic expressions for the time-dependent loss of enzyme activity
are given in Fig. 8c. Notably, the second-order rate constant for
a b c
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Asp387 Asp387Ala387
Fig. 6 Structure of TmGalA in complex with 4. a Structure of TmGalA mutant D387A in complex with intact 4. b Structure of TmGalA in complex with 2-
deoxy-2-ﬂuorocarbagalactose fragment of 4 covalently bound to the nucleophile D327. c Structure of TmGalA in complex with hydrolyzed inhibitor 6. The
maximum likelihood/σA weighted 2Fobs−Fcalc electron density map is contoured at 1.5 sigma in all cases. The catalytic residues D327 and D387 (or
D387A) residues are shown
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the catalyzed turnover of substrate (kcat/Km) is identical to the
corresponding rate constants for time-dependent inactivation
(kinact/Ki).
Considering that the two calculated second-order rate con-
stants kcat/Km and kinact/Ki are similar (the value for kcat/Km
assumes that the enzyme is 100% active, Table 1) and that no
curvature is discernible in Supplementary Fig. 3b, we conclude
that kcat ≈ k5 for turnover of 4 and likely for 3b as well. Thus the
half-lives of the two covalent intermediates formed during the
reactions of 3b and 4 with TmGalA are approximately 7 s and
20 min, respectively. Here the introduction of the 2-ﬂuoro group
retards hydrolysis of the covalent intermediate by a factor of
about 150, whereas the second-order rate constant (kcat/Km) for
formation of the covalent intermediate for the reaction of 3b is
400-fold larger than that for 4 (Table 1). That is, the ﬂuorine
substitution shows an approximate two-fold larger rate reducing
effect on covalent labeling of the enzyme than on dealkylation of
the resulting covalent intermediate. In contrast to the established
utility of activated 2-deoxy-2-ﬂuoro-β-D-glycosides as covalent
inhibitors of β-glycosidases26, the corresponding 2,4-dini-
trophenyl 2-deoxy-2-ﬂuorogalactoside (7) is rapidly hydrolyzed
by TmGalA through a reaction involving rate-determining gly-
cosylation (Table 1, k3 < k5). Conversely, we found that cyclo-
phellitol 8 is a slow time-dependent inactivator of TmGalA
(Table 1, Supplementary Figs. 6 and 7) with no reactivation of the
covalent enzyme intermediate over the course of 30 h (k5 ≈ 0).
Interestingly, these three distinct types of mechanism-based
inhibitors exhibit completely different reactivities. First, our car-
basugar analogs (3a, 3b, and 4) are covalent inhibitors that
rapidly alkylate TmGalA to give a colavently bound intermediate
that is slowly hydrolyzed to regenerate active enzyme. That is, our
compounds have the potential to show temporal effects of GH
activity and offer unique advantages as probe molecules in cells.
Second, cyclophellitol analog 8 is an inactivator of TmGalA and
thus other derivatives of this structural motif, such as the azir-
idines pioneered by Overkleeft44, can be used as chemical biology
probes for enzyme localization and quantiﬁcation, though not as
modulators of enzyme activity. Lastly, the 2-deoxy-2-
ﬂuoroglycoside 7 proved to be a substrate for TmGalA and
thus has little utility as a probe molecule.
The X-ray diffraction experiments provide an insight into the
enzyme-bound species and afford three structures that deﬁne
the reaction pathway for the two inversion events that occur at
the pseudo-anomeric center. These data enable us to analyze the
conformational changes that take place during the catalytic cycle
for the reaction of our cyclohexene covalent inhibitors. Speci-
ﬁcally, the formation of a covalent linkage between the pseudo-
anomeric carbon of 4 and the nucleophile of TmGalA (Asp327)
conﬁrms that this reaction occurs with inversion of
stereochemistry. Notably, the carbasugar ring binds in a ﬂat-
tened half-chair (2H3) conformation. An overlay of this struc-
ture with TmGalA in complex with intact 4 reveals that
formation of the covalent bond between the pseudo-anomeric
carbon (C1) and Asp327 necessitates signiﬁcant movement of
C1 (2.04 Å), C2, and C6 (the carbon atom in the position of the
endocyclic oxygen) and to a lesser extent C3, C4, and C5
(Fig. 9a). We note that all interactions with active site residues
for the carbasugar remain unchanged when compared to the
complex with 6.
Hydrolysis of the covalent intermediate gives the hydrolyzed
carbasugar 6, which binds in a similar position and with the same
conformation (2H3) as that observed for the carbasugar ring of
the Michaelis complex with 4 (Fig. 9b). Speciﬁcally, a signiﬁcant
motion of C1, C2, and C6 returns the cyclohexene ring to close to
its original position in the ﬁrst Michaelis complex (Fig. 9c). In the
complex with 6, the pseudo-anomeric carbon is displaced by 0.39
Å compared to its position in the complex of the D387A mutant
with 4.
The DFT/MM calculations show that the carbasugar ring of 4
in the initial Michaelis complex (Fig. 7a) has a 2H3 half chair
conformation, in agreement with the X-ray structure. This 2H3
half chair is slightly deformed towards a 4H3–1S3 conformation in
the fragment of 4 covalently bound to the nucleophile Asp327 in
the covalent intermediate (Fig. 7b). Of note, the DFT/MM opti-
mized structures and the conformations deduced from the X-ray
structure exhibit very similar puckering indices. Finally, the DFT/
MM optimized structure of the Michaelis product complex
(Fig. 7c) display a 2H3 half chair conformation while the X-ray
structure is classiﬁed as lying between a 2H3 half chair and a 2E
conformation. We extended our comparison between the QM/
MM and X-ray structures to the analysis of the interatomic dis-
tances between the sugar and the residues of the active site
(Supplementary Tables 6 and 7). Again, the agreement between
experiments and calculations is remarkable with both techniques
basically describing the same pattern of interactions. In addition,
we computed the energies for the interactions that occur within
the enzymatic active site between the inhibitor and the protein, an
analysis that is based on the QM/MM interaction energies as
shown in Supplementary Figs. 37 and 38. We found that inter-
actions with Trp190, Asp220, and Lys325 stabilize all species
along the reaction pathway. Also, Asp327 mediates a long-range
interaction between Trp65 and Trp257 that stabilizes the leaving
group fragment in the Michaelis complex E:I, an interaction that
is likely perturbed in the TmGalA D327A mutant used in the
crystallographic experiments. The total sugar–protein interaction
energies computed from the QM/MM and the X-ray structures
also conﬁrm the agreement between the results obtained from
these two complementary techniques (Supplementary Fig. 38).
In summary, we synthesized two cyclohexene carbasugars that
mimic both galactose and 2-deoxy-2-ﬂuorogalactose and have
determined their kinetic parameters for turnover and inhibition
with TmGalA. We show that our compounds are covalent inhi-
bitors but importantly not covalent inactivators. As a result, our
compounds inhibit GHs in a temporal fashion and enzyme
activity returns when the covalent–enzyme intermediate is
hydrolyzed. This is not the case for the cyclophellitol aziridine,
cyclosulfate inactivators, and other inactivators that include the
conduritol epoxides and most of the 2-deoxy-2-ﬂuoro-β-glyco-
sides. Therefore, our covalent inhibitors are functionally distinct
to the listed covalent inactivators and in principal allow
researchers to monitor cellular responses as enzyme activity
decreases and then subsequently returns to baseline levels. In
addition, we have provided structural insights into the con-
formations of the inhibitors at each step through the catalytic
cycle derived from X-ray diffraction analysis as well as from
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Fig. 8 Scheme for the covalent inhibition of α-glycosidases by cyclohexene
carbasugar analogs. a Mechanistic scheme showing individual rate
constants. b Kinetic expressions for hydrolysis of inhibitor. c Kinetic
expressions for the covalent labeling stopped-ﬂow experiments
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theoretical QM/MM calculations. Together these ﬁndings provide
a glimpse into the subtleties of GH catalysis, which will aid the
exploration of GH mechanisms and direct development of car-
bocyclic covalent inhibitors and inactivators of GHs.
Methods
Protein expression and puriﬁcation. A mutation, D387A, was introduced into the
plasmid encoding TmGalA using the QuikChange Site-directed Mutagenesis Kit
(Stratagene, La Jolla, CA) using primers ForD387A, 5′-GATGAGGATAGGACC
TGCTACTGCGCCGTTCTGGG-3′ and RevD387A, 5′-CCCAGAACGGCGCA
GTAGCAGGTCCTATCCTCATC-3′. The plasmid encoding either α-galactosidase
TmGalA or TmGalA with the D387A mutation was transformed into Escherichia
coli BL-21(DE3) cells. TmGalA and the D387A mutant were expressed recombi-
nantly by growing cultures at 37 °C in Luria-Bertani broth containing kanamycin
(50 µgmL–1), until an optical density at 600 nm of approximately 0.6 absorbance
units was reached. Overexpression was induced by the addition of 0.5 mM isopropyl
β-D-1-thiogalactopyranoside, and cells were cultured for a further 4 h at 37 °C. Cells
were harvested by centrifugation, re-suspended in phosphate-buffered saline (PBS),
pH 7.4, 20mM imidazole, and lysed using a cell disruptor at 30 kpsi. TmGalA was
applied to a nickel afﬁnity chromatography column (5 mL HisTrap FF, GE
Healthcare), washed with 10 column volumes of PBS, pH 7.4, and 50mM imidazole,
and eluted with 5 column volumes of PBS, pH 7.4, and 250mM imidazole. TmGalA
was buffer exchanged into 20mM HEPES, pH 7.4, 150mM NaCl (HiPrep 26/10
desalting column, GE Healthcare) and then applied to a size-exclusion column
(Superdex 200 16/60, GE Healthcare) for further puriﬁcation. TmGalA was judged
to be >95% pure by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Enzyme kinetics. Michaelis–Menten kinetic parameters for the hydrolysis of the
cyclohexene carbasugar mimics of galactose (3), 2-deoxy-2-ﬂuorogalactose (4) and
the substrate 2,4-dinitrophenyl 2-deoxy-2-ﬂuorogalactoside (7) were determined
from a minimum of six initial rate measurements using a concentration range of at
least Km/4 to 4 × Km. The progress of each reaction was monitored continuously for
5 min at 400 nm using a Cary 300 UV-vis spectrometer equipped with a tem-
perature controller. Each 500 μL reaction mixture was prepared by addition of the
appropriate volume of buffer (50 mM HEPES buffer, pH 7.4, T= 37 °C), substrate
and enzyme. The rate versus substrate concentration data were ﬁt to a
Michaelis–Menten equation using a standard nonlinear least-squares computer
program (Prism 7.0).
All covalent inhibition experiments with 4 were performed at 37 °C in 50 mM
HEPES buffer, pH 7.4 using an Applied Photophysics SX18 stopped-ﬂow
spectrophotometer, equipped with an external temperature controller. The
stopped-ﬂow spectrometer was used in the sequential double mixing mode, in
which rapidly mixed enzyme and inhibitor 4 were incubated for various time
intervals prior to rapid mixing of the enzyme/inhibitor solution with a buffered
solution of 4-nitrophenyl α-D-galactopyranoside. The remaining enzyme activity
was monitored at a wavelength of 400 nm. Pseudo ﬁrst-order rate constants for loss
of enzyme activity (kobs) at each inhibitor concentration were calculated by ﬁtting
the absorbance versus time data to a standard ﬁrst-order rate equation using a
nonlinear least squares routine in Prism 7.0. The kinetic parameters for
inactivation by cyclophellitol 8 were determined using a classical dilution assay that
involved preincubation of the enzyme with varying concentrations of inhibitor at
37 °C in 50 mM HEPES buffer, pH 7.4 containing bovine serum albumin (BSA;
1 mgmL–1). The remaining enzyme activity was measured periodically by
removing an aliquot (10 µL) and adding it to a pre-equilibrated solution (37 °C)
containing 4-nitrophenyl α-D-galactopyranoside (250 µM) in HEPES buffer (50
mM, pH= 7.4, [BSA]= 1 mgmL–1). The ﬁrst-order rate constants for inactivation
(kobs) were determined by ﬁtting the absorbance versus time data to a standard
ﬁrst-order rate equation. The ﬁrst- and second-order rate constants (kinact and
kinact/Ki) for inactivation were calculated by ﬁtting the rate constant data versus the
inactivator concentration to a standard Michaelis–Menten equation (Prism 7.0).
Crystallization. TmGalA (10mgmL–1) was crystallized from 0.2M MgSO4 and 20%
(w/v) poly(ethylene glycol) (PEG) 3350, and crystals were soaked in 30% (w/v) PEG
3350 containing 1mM inhibitor 3a overnight or in 0.2M MgSO4 and 30% (w/v) PEG
3350 containing a minute amount of inhibitor 4 added as powder for either 2 min or
1 h. The TmGalA mutant D387A (10mgmL–1) was crystallized from 0.2M MgSO4
and 20% (w/v) PEG 3350, and crystals were soaked in 30% (w/v) PEG 3350 con-
taining 2mM inhibitor 3a for 2 h. The TmGalA mutant D387A (10mgmL–1) was
incubated with ~1mM inhibitor 4 and co-crystallized from 0.2M MgSO4 and 20%
(w/v) PEG 3350. All crystals were cryo-protected in 0.2M MgSO4 and 30% (w/v)
PEG 3350 prior to vitriﬁcation in liquid nitrogen.
Data collection and processing. X-ray diffraction data were collected at Diamond
Light Source (DLS) (TmGalA mutant D387A in complex with 3a, beamline I04-1;
TmGalA in complex with 5, beamline I04-1; TmGalA in covalent complex with
fragment of 4, beamline I03) or the European Synchrotron Radiation Facility
(TmGalA mutant D387A in complex with 4, beamline ID29; TmGalA in complex
with 6, beamline ID29). Data processing and reﬁnement statistics are listed in
Supplementary Tables 1 and 2. Diffraction data were processed using the Xia248
pipeline to run DIALS or XDS49 with Aimless50 from the CCP4 suite51. Molecular
replacement was performed using MOLREP52 or Phaser53 with Protein Data Bank
(PDB) entry 5M0X as the search model. Reﬁnement was performed using
REFMAC554 and manual model building was done using Coot55. Structures were
validated using PDB_REDO56. Models for the inhibitors were built in JSME57 and
the library was generated with PRODRG58.
Starting structure for theoretical simulations. The starting structure for the
computer simulations of the inhibition and hydrolysis of inhibitor 4 by TmGalA)
was the structure PDB code 5M1223. This structure corresponds to the structure of
TmGalA in complex with an intact cyclopropyl carbasugar. The structure of the
cyclopropyl carbasugar was modiﬁed to correspond to inhibitor 4. Missing atoms
of Glu80 and Lys77 residues in X-ray structure were added using Accelrys Dis-
covery Studio Visualizer v 4.559. The charges and parameters for inhibitor 4,
obtained using the Antechamber software package along with a general AMBER
force ﬁeld (GAFF)60, are listed in Supplementary Table 3. Hydrogen atoms were
added using the tLEAP61 module of Amber Tools program. The protonation state
of titratable amino acids at pH 7.4 was determined using pKa results calculated
using PROPKA ver. 3.162 available on PDB2PQR server63. The results indicate that
Asp 387 and Glu 459 are present in their protonated form. Additionally, Glu224
was protonated to allow more favorable hydrogen bonding between neighboring
Asp221 and inhibitor 4. Furthermore, His30 and His273 were protonated at the
a b
1.67 Å 2.04 Å 
c
Fig. 9 Superposition of TmGalA structures. a Structure of TmGalA mutant D387A in complex with intact 4 (cyan) and of wild-type TmGalA in complex with
2-deoxy-2-ﬂuorocarbagalactose fragment of 4 covalently bound to the nucleophile Asp327 (yellow). b Structure of wild-type TmGalA in complex with
hydrolyzed inhibitor 6 (pink) and of wild-type TmGalA in complex with 2-deoxy-2-ﬂuorocarbagalactose fragment of 4 covalently bound to the nucleophile
Asp327 (yellow). c Structure of TmGalA mutant D387A in complex with intact 4 (cyan) and of wild-type TmGalA in complex with hydrolyzed inhibitor
6 (pink)
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δ-position, while the rest of histidine residues were protonated at the ε-position.
Neutralization of the total charge of the system was made by addition of 17 sodium
cations (Na+) in the electrostatically most favorable positions. Next, the system was
placed in orthorhombic box of TIP3P64 water molecules with size of 89 × 96 × 79
Å3. The geometries of the remaining water molecules were then optimized. The full
system was formed by the protein (8453 atoms), the substrate (37 atoms in E:I, 23
atoms in E-I and 25 atoms in E:P), and 17,398 solvation water molecules (52,194
atoms).
MM MD simulations. After performing the A387D reverse mutation and setting
up the model, NAMD software65 with the AMBER force ﬁeld66 was used to run
classical molecular dynamics (MD) simulations with the full solvated protein to
equilibrate the system. In all, 10 ns of classical MD simulation (at temperature
310 K) was carried out in the NVT ensemble using the Langevin–Verlet algorithm
to equilibrate the system at the E:I state, after heating from 0 to 310 K with 0.001 K
temperature increment. Periodic boundary conditions using the particle mesh
Ewald method were applied. In order to improve time of calculations, a cut-off for
nonbonding interactions was applied using a smooth switching function with
between 14.5 to 16 Å. The time dependence of root mean square deviation, tem-
perature, total energy, and ﬂuctuation of Cα positions during the MD simulation
are plotted in Supplementary Figure 34, while a graphical representation of the B-
factor values on the protein as well as its population analysis are reported in
Supplementary Figure 35. The results indicate that the system can be considered
equilibrated after 10 ns of the MD simulation. The structure of TmGalA appears to
be quite rigid, with no dramatic ﬂuctuations during MD simulations (the max-
imum value of B-factor was 7.4 Å2).
QM/MM optimizations. The last structure from the 10 ns MM MD simulation of
E:I complex was used to run the QM/MM calculations using fDynamo library67
(Supplementary Figs. 39 and 40). In order to reduce time of calculations, positions
of atoms presented beyond 20 Å from the inhibitor 4 were ﬁxed. The QM subset of
atoms were described ﬁrst by the semiempirical AM1 Hamiltonian and later with
the M06-2×68 hybrid functional and the 6-31+G(d,p) basis set, as described below.
The protein and water molecules were described with the OPLS69 and TIP3P64
classical force ﬁelds, respectively. fDynamo library67 combined with Gaussian 0970
were used for all the QM/MM calculations. Structures of the corresponding stable
states for the formation of the covalent intermediate between the inhibitor 4 and
the protein and its hydrolysis, E:I, E-I, and E:P, were ﬁrst optimized at AM1/MM
level of theory. E-I and E:P were located from the previously equilibrated Michaelis
complex, E:I, by modifying the interatomic distances d(OD2Asp327−C1), d
(C1–OLg), d(OD2Asp387−HAsp387), and d(HAsp387−OLg). Thus, once the covalent
bond between Asp327 and C1 atom of the sugar ring of inhibitor 4 was formed
(intermediate E-I:Lg), the leaving group, Lg, was removed from the system and the
cavity was ﬁlled with 5 water molecules. Next, 500 ps of QM/MM MD was run
where the position of all atoms beyond distance of 20 Å from the substrate was
ﬁxed, thus generating the E-I intermediate after equilibration. Finally, the hydro-
lysis of this covalent intermediate and generation of compound 6 in the active site,
E:P, was obtained by controlling the distances d(OWAT−C1), d(C1–OAsp327), d
(OD2Asp387–HWAT) and d(HWAT–OAsp387). The structure was then fully opti-
mized without constraints.
Both Asp327 and Asp387 together with full inhibitor 4 were included in the
QM region to locate the covalent intermediate, E-I. The two aspartate residues, the
remaining part of inhibitor and one water molecule were described at QM level in
the generation of the hydrolyzed inhibitor in the cavity of the protein, E:P. To
saturate the valence of the QM/MM frontier atoms, link atoms were placed in the
frontier QM–MM bonds of the two aspartate residues, as depicted in
Supplementary Figure 39. Finally, the three key structures (E:I, E-I, and E:P) were
optimized at M06-2×/OPLS-AA/TIP3P level, using the 6-31+G(d,p) basis set for
the treatment of the QM subset of atoms.
QM/MM MD simulations. After the structures of the stationary points, Michaelis
complex (E:I), covalent intermediate (E-I), and products (E:P) were optimized,
100 ps AM1/MM MD simulations were done in order to obtain statistical repre-
sentation of these structures. Subsequent analysis of geometries and interaction
energies was done based on 1000 structures.
Puckering coordinates of the ring: Two different formalisms have been used to
deﬁne the puckering of the ring in the three key states of the full conformational
itinerary: the one based on the Cremer–Pople puckering coordinates46 and the
angles used in the Hill and Reilly method47. The results are reported in
Supplementary Table 4 and in Supplementary Figure 36.
Individual interaction energies by amino acid. The contributions of individual
amino acid residues to the inhibitor stabilization were computed (in kcal mol–1) as an
average of the total QM–MM interaction energy over 1000 structures generated along
the AM1/MM MD simulations initiated from optimized structures for the different
TmGalA structures: intact 4; 2-deoxy-2-ﬂuorocarbagalactose fragment of 4 covalently
bound to the nucleophile Asp327; and inhibitor 6 (see Supplementary Table 8 and
Supplementary Figs. 37 and 38). Owing to the fact that this magnitude is directly
obtained from the QM–MM interaction term of the full QM/MM Hamiltonian, only
the atoms of compound 4 were included in the QM region (not Asp327 or Asp387) in
the ﬁrst case, E:I (Supplementary Fig 37A). For the E-I state (Supplementary Fig. 37B)
and since the fragment of compound 4 was covalently bounded to the protein, only
this fragment of the compound and the sidechain of Asp327 were included in the QM
region. Finally, for the E:P state (Supplementary Fig. 37C), only the hydrolyzed
inhibitor, compound 6, was included in the QM region.
The analysis of the interactions energies in the E-I state as plotted in
Supplementary Figure 37B has to be carried out with caution due to the fact that
Asp327 is covalently bound to the fragment of 4, and the interactions that appear
in the ﬁgure can be established with this residue and not with the fragment of
inhibitor 4. This is the case of Trp65 and Arg383, the repulsive interaction with
Asp425, or the overestimated stabilizing interaction established with the positively
charged Lys325. Nevertheless, as observed, the remaining favorable interactions are
in agreement with the geometrical analysis that can be deduced from the inter-
atomic distances (Supplementary Tables 5–7). Finally, when comparing the
interactions of 6 (Supplementary Fig. 37C) with those established in 5, less intense
interactions are measured but a similar pattern is detected.
Data availability
The accession codes for the structures reported in this article are: 6GTA, 6GVD, 6GWF,
6GWG, and 6GX8. All other data that support the ﬁndings of this study are available
from the corresponding authors upon reasonable request.
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